

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Prevalence and clinical presentations of post-COVID-19 conditions in Nepal

Lila Bahadur Basnet^{1, #a}, Pomawati Thapa^{1, #b}, Anup Bastola¹, Narendra Khanal^{1, #c}, Niranjan Panta¹, Sabin Thapaliya², Melissa Beth Kleine Bingham³, Saugat Shrestha³, Shital Adhikari³, Sudesha Khadka^{3*}, Priyanka Shrestha³, Sadhana Paudel³, Kamaraj Arulmozhi Devapitchai³

¹Department of Health Services, Curative Service Division, Ministry of Health and Population, Kathmandu, Nepal

²Department of Internal Medicine (Infectious Diseases), Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu

³World Health Organization, Country office for Nepal, Pulchowk, Lalitpur

^{#a}Current Address: College of Public Health, The University of Iowa, Iowa City, United States of America

^{#b} Current Address: Department of Health Services, Epidemiology and Disease Control Division, Ministry of Health and Population, Kathmandu, Nepal

^{#c} Current Address: Department of General Practice and Emergency Medicine, Bir Hospital, Kathmandu, Nepal

*Corresponding author

E-mail: khadkasudesha@gmail.com/ khadkas@who.int (SK)

22

23 **Abstract**

24 **Introduction:**

25 The COVID-19 pandemic affected millions worldwide. While the major focus was on diagnosis
26 and treatment of the acute phase of the disease, many individuals experienced long-term health
27 even after recovery. These post-COVID-19 conditions encompass a broad range of physical,
28 psychological, and cognitive symptoms that persist beyond the acute phase of the illness. The aim
29 of this study was to find the prevalence and reported presentations of post-COVID-19 conditions
30 in Nepal.

31

32 **Method:**

33 This is a retrospective cross-sectional study using structured questionnaire to collect hospital-based
34 data available in the record of Curative Service Division, Department of Health Services of Nepal
35 from October 2021 to September 2022. A total of 6151 cases were recorded in the study.
36 Descriptive analysis was done for demographic and symptoms variable. Association of variables
37 to post-COVID-19 condition are shown using univariate and multivariate logistic regression.

38

39 **Results:**

40 Among 6151 respondents (62.25% males), more than half (59.03%) had at least one symptom after
41 recovery from acute COVID-19. The most common symptoms were anxiety (28.5%), loss of
42 appetite (25.3%), shortness of breath (24.13%), fatigue (23.24%), depressed mood (18.79%),
43 muscle ache (17.59%), chest pain (16.81%), headache (14.78%), and palpitation (13%).
44 Multivariate analysis showed increased odds of post-COVID-19 conditions in smokers (adjusted

45 OR [aOR] 1.53), those with chronic lung disease (aOR 1.71), neurological disorder (aOR 2.43)
46 and those with use of supplementary oxygen during acute illness of COVID-19 (aOR 3.37).

47

48 **Conclusion:**

49 The prevalence of post-COVID-19 symptoms among the study population is found to be high. The
50 main symptoms from our study and similar studies are anxiety, fatigue, loss of appetite, shortness
51 of breath, muscle pain, headaches. Patients with smoking, hypoxia during acute illness and
52 presence of chronic lung disease and neurological disorder had higher odds of getting post-
53 COVID-19 conditions. Citing the findings, health system should focus upon the management and
54 recording of such conditions for further evidence.

55

56

57

58 **Introduction**

59

60 The COVID-19 pandemic affected millions of individuals worldwide causing significant
61 morbidity and mortality. While the immediate focus had been on diagnosing and treating the acute
62 phase of the disease, there is growing recognition of the long-term health consequences
63 experienced by individuals recovering from COVID-19 [1,2]. These post-COVID-19 conditions,
64 commonly referred to as "long COVID" or "post-acute sequelae of SARS-CoV-2 infection"
65 (PASC), encompass a broad range of physical, psychological, and cognitive symptoms that persist
66 beyond the acute phase of the illness [3].

67 Several studies carried out to understand the features of post-COVID conditions have shown wide
68 range of symptoms affecting the individual's ability to perform daily activities [4,5]. Though most
69 people who developed COVID-19 fully recovered, approximately 10-20% experience a variety of
70 mid- and long-term effects. The effects of the pandemic, lockdowns, quarantine, and isolation may
71 also have long-term impact. There are no tests or pathognomonic findings to establish the diagnosis
72 of post-COVID-19 conditions. Additionally, there is variability of definition and the terminology
73 used around long-COVID. The definition developed by Delphi consensus by the WHO should
74 help bring uniformity in the research and hence the data related to post-COVID-19 condition [4].
75 Patients with post-COVID-19 condition require further healthcare services including support
76 group for post-COVID-19 condition has been widely acknowledged for their support and recovery
77 [1]. The identification of the post-COVID-19 conditions and its burden would be the basis for
78 allocation of resources and plan for needs [5].
79 Few studies have been carried out in a single setting on post-COVID-19 conditions with limited
80 information and evidence on post-COVID-19 conditions across Nepal. This study aimed to find
81 out the prevalence and types of post-COVID symptoms in Nepalese population.

82
83
84
85
86
87

88 **Method**

89 **Study Design and Setting**

90 A cross-sectional study using secondary data from the electronic record and paper-based record of
91 Curative Service Division (CSD) of Department of Health Services was conducted. CSD hosted
92 the program on post-COVID and lead on the preparation of the treatment protocol for the
93 Management of Post-COVID patients. CSD is also responsible for the provision of basic health
94 services and coordination with hospitals during and beyond the COVID-19 situation.

95 **Study population**

96 Data (both electronic based and paper based) was recorded between October 2021 through
97 September 22 and included those who recovered from acute illness of COVID-19. The data was
98 accessed on 20th July 2023 from CSD. De-identification of accessed data was done and data with
99 incomplete information were excluded from the study.

100

101 **Study tools and techniques**

102 A structured questionnaire was used to collect hospital-based data available in the record of CSD.
103 The structured questionnaire was developed with reference from module 1 and module 2 of WHO
104 Case Report Form (CRF) for post-COVID condition.

105

106 **Study Variable**

107 Demographic details, prior comorbidities, symptoms during acute COVID-19, hospitalization and
108 oxygen use during acute COVID-19, symptoms of post-COVID-19 conditions, and history of
109 vaccination against COVID-19 were collected. Fever and cough were excluded in the analysis

110 because it was not clear in the record whether these symptoms reported were present in acute
111 illness or continued after recovery. Post-COVID condition in this study is described the presence
112 of at least one persistent or newly developed symptom one month after recovery from acute illness
113 of COVID-19, in absence of or are not explained by other disease.

114

115 **Statistical analysis**

116 The data collected from the records were entered in Excel. Data were analyzed using Stata (version
117 17). Descriptive analysis was conducted and presented as frequencies and proportions for
118 categorical variables. Associations of post-COVID-19 symptoms with prior comorbidities and
119 various demographic data were analyzed using univariate and multivariate logistic regressions. A
120 p-value of <0.05 was considered statistically significant.

121

122 **Ethical consideration**

123 Ethical approval was obtained from National Health Research Council Ethical Review Board.
124 Permission to access data was obtained from the Curative Service Division. The secondary data
125 was used without a personal identifier.

126

127 **Results**

128 Of the total 6180 observations screened, 6151 observations were included in the study and the
129 largest number was from the 30-39 years age group. More than half (62.25%) of the individuals
130 were male (Table 1). The prevalence of post-COVID-19 condition (defined here as the presence
131 of at least one symptom one month after recovery from acute COVID) was 59.03%.

132

133 **Table 1. Socio-demographic characteristics of the screened post-COVID-19 cases**

Variables	Frequency	Percentage
Age group		
<=9 years	31	0.5%
10-19	140	2.3%
20-29	1417	23.0%
30-39	1662	27.0%
40-49	1094	17.8%
50-59	797	13.0%
60-69	566	9.2%
70-79	309	5.0%
80-89	126	2.0%
90 and above	9	0.1%
Sex		
Male	3829	62.3%
Female	2316	37.7%
Others	6	0.1%

134

135 As shown in Table 2, individuals had a variety of symptoms, and many had more than one
136 symptom. The most common symptoms were anxiety (28.5%), loss of appetite (25.3%), shortness
137 of breath (24.13%), fatigue (23.24%), depressed mood (18.79%), muscle ache (17.59%), chest

138 pain (16.81%), headache (14.78%), and palpitation (13%). It was found that more than half
139 (59.03%) had at least one symptom after recovery from acute COVID-19.

140 **Table 2: Characteristics of post-COVID-19 conditions (n = 6,151)**

141

Variables	Frequency (n = 6151)	Percentage
General Symptoms		
Fatigue	1430	23.24%
Skin rash	244	3.96%
Cardiorespiratory symptoms		
Dyspnea	1484	24.13%
Chest pain	1034	16.81%
Palpitation	800	13.0%
Neurology		
Headache	909	14.78%
Limb weakness	597	9.71%
Problem with gait	532	8.65%
Tremor	343	5.57%
Dizziness	306	4.97%
Numbness/tingling	225	3.65%
Fainting/Blackouts	57	0.93%
Mental symptoms		
Anxiety	1753	28.50%
Depressed mood	1156	18.79%

Trouble concentrating	460	7.48%
Behavioral change	362	5.89%
Brain Fog	349	5.67%
Hallucination	54	0.94%
Gastrointestinal and Reproductive		
Loss of appetite	1556	25.30%
Vomiting	662	10.76%
Diarrhea	603	9.80%
Constipation	510	8.29%
Abdominal pain	383	6.23%
Loss of libido	216	3.51%
Rheumatologic		
Muscle ache	1082	17.59%
Joint pain	630	10.24%
Muscle stiffness	132	2.15%
Menstrual symptoms (n = 2060)		
Irregular menstruation	173	8.4% *
Dysmenorrhea	103	5.00% *

142 * Percentage among menstruating women

143

144 Overall, neuropsychiatric symptoms were the most prevalent followed by cardiorespiratory
 145 symptoms. The common neuropsychiatric manifestations are shown in Fig 1.

146

n = 6151

147 **Fig 1: The neuropsychiatric symptoms (shown in percentage)**

148
 149 Smokers (adjusted OR [aOR] 1.53, 95% Confidence Interval [CI] 1.34- 1.75), those with chronic
 150 lung disease (aOR 1.71, 95% CI 1.22 – 2.39), neurological disorder (aOR 2.43, 95% CI 1.39-4.26),
 151 use of supplementary oxygen during acute illness of COVID-19 (aOR 3.37, 95% CI 2.90-3.91)
 152 and vaccination (any) against COVID-19 (aOR 1.72, 95% CI 1.53-1.94) had higher odds to get
 153 post-COVID-19 condition after recovery from acute illness of COVID-19 even after adjusting for
 154 other covariates.(Table 3)

155

156 **Table 3: Univariate and multivariate logistic regression for outcome variables**

157

Variables	OR (95% CI)	p-value	aOR (95% CI)	p-value
Smoker	1.53 (1.36-1.72)	<0.001	1.53 (1.34-1.75)	<0.001
Male	0.71 (0.64-0.79)	<0.001	0.66 (0.58-0.74)	<0.001
Hypertension	1.76 (1.52-2.05)	<0.001	1.12 (0.93-1.35)	0.24
Diabetes	1.67 (1.41-1.97)	<0.001	1.08 (0.87-1.32)	0.49
Chronic Liver Disease	1.52 (1.01-2.31)	0.046	1.26 (0.61-2.60)	0.53
Chronic Kidney Disease	1.01 (0.71-1.43)	0.96	0.51 (0.30-0.84)	0.009
Chronic lung disease	2.43 (1.84-3.20)	<0.001	1.71 (1.22-2.39)	0.002
Neurological disorder	2.21 (1.52-3.22)	<0.001	2.43 (1.39-4.26)	0.002
Malignancy	1.44 (0.94-2.22)	0.098	0.44 (0.19-0.99)	.046
Vaccination	1.15 (1.03-1.28)	0.009	1.72 (1.53-1.94)	<0.001

History of ICU/HDU admission	2.17 (1.93-2.44)	<0.001	1.04 (0.89-1.21)	0.47
History of receiving Oxygen therapy	3.42 (3.05-3.83)	<0.001	3.37 (2.90-3.91)	<0.001

158 For regression, remaining categories in each variable were taken as reference.

159

160 Discussion

161 Analyzing the record of 6151 individuals with history of COVID-19 obtained, more than half were
162 found to be symptomatic. Individuals reported plethora of symptoms ranging from anxiety loss of
163 appetite shortness of breath, fatigue, persistent pain in muscles, and persistent headache. This is
164 similar to the findings from a study done in China by Huang Lixue et. al, in which the proportion
165 of patients with at least one sequelae symptom was found to be 68% (831/1227) at 6 months and
166 49% (620/1272) at 12 months. Furthermore, after one-year individuals with anxiety as a health
167 problem constituted 26 % [331/1271] and those having dyspnea were 30% [380/1271] [2]. Another
168 study done by Maxime Taquet et. al. reports 57% of the patients after whole 6 months had at least
169 one symptom [3].

170 The prevalence of post-COVID-19 symptoms are being measured worldwide and attempts has
171 been made to quantify the presentations. There are variety of presentations that are difficult to
172 collate and link to the previous COVID-19 status and hence the under-reporting is obvious. An
173 analysis of the data from over 250,000 electronic health records also shows more than 33%
174 presenting with the features of post-COVID-19 condition recorded between 3 and 6 months after
175 a diagnosis of COVID-19 [6].

176 In a study published by B Anup et. al. from Nepal, dyspnea, fatigue, chest heaviness, and cough
177 were the commonest persistent complaints with 82.2% of the patients presenting with at least one
178 symptom [7].

179 Similarly, another study conducted among 300 patients in a tertiary center of Nepal shows fatigue
180 as the most common persistent symptom after COVID-19 illness when followed up after 3 months.
181 The other symptoms reported in this study are sore throat, rhinitis, diarrhea, anosmia, ageusia and
182 shortness of breath [8].

183 Different studies have shown a variety of symptoms that is linked to the previous COVID-19
184 illness. The duration of follow-up and the severity of illness might play a significant role in the
185 outcomes. Globally, while there has been much effort to establish a common set of
186 symptoms/outcomes for long-COVID, the variance and wide range of reported symptoms makes
187 this challenging [6].

188 This study also found that smokers, patients with chronic lung disease, neurological disorder and
189 those with use of supplementary oxygen during acute illness of COVID-19 had more prevalence
190 of symptoms. In a systemic review and meta-analysis by Tsampasian V et al comprising 41 studies
191 including 860 783 patients, smoking (OR, 1.10; 95% CI, 1.07-1.13, underlying co-morbidities
192 (OR, 2.48; 95% CI, 1.97-3.13), and hospitalization and ICU admission (OR, 2.37; 95% CI, 2.18-
193 2.56) were found to be the risk factors for development of post-COVID-19 conditions [9]. Multi-
194 regression analysis in their study did not show diabetes and ischemic heart disease increasing the
195 risk of post-COVID-19 conditions as observed in this study.

196 Males had lower odds of post-COVID-19 symptoms compared to females and this could be
197 because of the inclusion of menstrual problems and also the increased tendency to report non-
198 specific symptoms among females [10]. Similar findings have been reported in a multicenter study
199 conducted in Spain [11].

200 People vaccinated against COVID had higher odds of post-COVID-19 symptoms than those who
201 were not vaccinated. This contrasts with what has been reported elsewhere [9]. This could be
202 because the symptoms following vaccination are similar to the post-COVID-19 conditions and
203 could have been reported as post-COVID-19 symptoms [9,12]. However, this requires further
204 investigation and was beyond the scope of this study.

205 Our study points to the need of tracking the patients who were hospitalized for the COVID-19
206 patients in hospitals of Nepal. As the COVID-19 pandemic placed the hospitals in unprecedented
207 public health crisis, the acute illness management had been obvious primary focus. However, the
208 growing evidence of post-COVID conditions warrants the shift in focus and consider COVID-19
209 as an alternative diagnosis if that is co-related.

210

211 Conclusion:

212 The prevalence of post-COVID-19 symptoms among the study population is found to be high. The
213 main symptoms from our study and other similar studies include anxiety, fatigue, loss of appetite,
214 shortness of breath, muscle pain and headache. Patients who smoked, had hypoxia during acute
215 illness, had presence of chronic lung disease or neurological disorder had higher odds of getting
216 post-COVID-19 conditions. Citing the findings, health system should focus upon the management
217 and recording of such conditions for further evidence.

218

219 Acknowledgment

220 We would like to express our sincere gratitude to Dr. Roshan Pokharel, the Secretary of the
221 Ministry of Health and Population, and Dr. Rajesh Sambhajirao Pandav, Country Representative
222 for WHO, Nepal for their overall leadership and support in developing this research manuscript.

223 We are also deeply grateful to all individuals who are directly or indirectly involved in the entire
224 process from conceptualization to the publication stage including those whose details are included
225 in the study.

226 **References:**

- 227 1. McNaughton CD, Austin PC, Sivaswamy A, Fang J, Abdel-Qadir H, Daneman N, et al.
228 Post-acute health care burden after SARS-CoV-2 infection: a retrospective cohort study. *C*
229 *Can Med Assoc J.* 2022 Oct 17;194(40):E1368–76. PubMed PMID: 36252983; PubMed
230 Central PMCID: PMC9616149.
- 231 2. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital
232 survivors with COVID-19: a longitudinal cohort study. *Lancet.* 2021 Aug
233 28;398(10302):747–58. PubMed PMID: 34454673; PubMed Central PMCID:
234 PMC8389999.
- 235 3. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-
236 occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study
237 of 273,618 survivors of COVID-19. *PLoS Med.* 2021 Sep 28;18(9):e1003773. PubMed
238 PMID: 34582441; PubMed Central PMCID: PMC8478214.
- 239 4. World Health Organization [Internet]. Coronavirus disease (COVID-19): Post COVID-19
240 condition. [cited 2023 Aug 24]. Available from: Coronavirus disease (COVID-19): Post
241 COVID-19 condition (who.int)
- 242 5. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al.
243 (2021) Burden of post-COVID-19 syndrome and implications for healthcare service
244 planning: A population-based cohort study. *PLoS ONE* 2021 Jul 12;16(7): e0254523.
245 PubMed PMID: 34252157; PubMed Central PMCID: PMC8274847.

- 246 6. Munblit D, Nicholson TR, Needham DM, Seylanova N, Parr C, Chen J, et al. Studying the
247 post-COVID-19 condition: research challenges, strategies, and importance of Core
248 Outcome Set development. *BMC Med.* 2022 Feb 4;20(1):50. PubMed PMID: 35114994;
249 PubMed Central PMCID: PMC8813480.
- 250 7. Bastola A, Nepal R, Shrestha B, Maharjan K, Shrestha S, Chalise BS, et al. Persistent
251 Symptoms in Post-COVID-19 Patients Attending Follow-Up OPD at Sukraraj Tropical and
252 Infectious Disease Hospital (STIDH), Kathmandu, Nepal. *Trop Med Infect Dis.* 2021 Jun
253 28;6(3):113. PubMed PMID: 34203115; PubMed Central PMCID: PMC8293320.
- 254 8. Shah S, Bhattarai SR, Basnet K, Adhikari YR, Adhikari TB, Bhatta N, et al (2022) Post-
255 COVID syndrome: A prospective study in a tertiary hospital of Nepal. *PLoS One.* 2022 Aug
256 10;17(8):e0272636. PubMed PMID: 35947595; PubMed Central PMCID: PMC9365179.
- 257 9. Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk
258 Factors Associated With Post–COVID-19 Condition: A Systematic Review and Meta-
259 analysis. *JAMA Intern Med.* 2023 Jun 1;183(6):566–80. PubMed PMID: 36951832;
260 PubMed Central PMCID: PMC10037203
- 261 10. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. *J Gen
262 Intern Med.* 2001 Apr;16(4):266-75. PubMed PMID: 11318929; PubMed Central PMCID:
263 PMC1495200
- 264 11. Fernández-De-las-peñas C, Martín-Guerrero JD, Pellicer-Valero ÓJ, Navarro-Pardo E,
265 Gómez-Mayordomo V, Cuadrado ML, et al. Female Sex Is a Risk Factor Associated with
266 Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The
267 LONG-COVID-EXP-CM Multicenter Study. *J Clin Med.* 2022 Jan 14;11(2):413. PubMed
268 PMID: 35054108; PubMed Central PMCID: PMC8778106.
- 269 12. Hosseini R, Askari N. A review of neurological side effects of COVID-19 vaccination. *Eur*

270 J Med Res. 2023 Feb 25; 28(1):102. PubMed PMID: 36841774; PubMed Central
271 PMCID: PMC9959958

272 13. Chen C, Hauptert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of
273 Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis
274 and Systematic Review. J Infect Dis. 2022 Nov 1;226(9):1593-1607. PubMed PMID:
275 35429399; PubMed Central PMCID: PMC9047189

276

277

278

279

